Evaluation of potential retinal toxicity of adalimumab (Humira)

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 247, Issue 8, 2009, Pages 1119-1125

  Tsilimbaris, Miltiadis ^a   Diakonis, Vasilios F ^a,b   Naoumidi, Irini ^a   Charisis, Spyridon ^b   Kritikos, Iraklis ^c   Chatzithanasis, George ^a   Papadaki, Thekla ^b   Plainis, Sotiris ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY OF CRETE   (Greece)

^c UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Adalimumab; Anti TNF; Humira; Intravitreal injection; Retinal toxicity

Indexed keywords

ADALIMUMAB; BALANCED SALT SOLUTION;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; ELECTRORETINOGRAM; ENUCLEATION; EXPERIMENTAL MODEL; FOLLOW UP; HISTOPATHOLOGY; INFECTION; INFLAMMATION; MALE; NIGHT VISION; NONHUMAN; OPHTHALMOSCOPY; PHOTOPIC VISION; PRIORITY JOURNAL; RABBIT; RETINA DISEASE; SLIT LAMP; TOXICITY TESTING;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ELECTRORETINOGRAPHY; INJECTIONS; MALE; RABBITS; RETINA; TUMOR NECROSIS FACTOR-ALPHA; VITREOUS BODY;

EID: 67651098926     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-009-1065-y     Document Type: Article

References (39)

1. Theodossiadis PG, Markomichelakis NN, Sfikakis PP (2007) Tumor necrosis factor antagonists: Preliminary evidence for an emerging approach in the treatment of ocular inflammation. Retina 27(4):399-413, doi: 10.1097/ MAJ.0b013e3180318fbc
2. Santos Lacomba M, Marcos Martín C, Gallardo Galera JM, Ǵmez Vidal MA, Collantes Estévez E, Ramírez Chamond R, Omar MM (2001) Aqueous humor and serum tumor necrosis factor-a in clinical uveitis. Ophthalmic Res 33:251-255, doi: 10.1159/000055677
3. Palexas GN, Sussman G, Welsh NH (1992) Ocular and systemic determination of IL-1 beta and tumor necrosis factor in a patient with ocular inflammation. Scand J Immunol 11(Suppl):173-175, doi: 10.1111/ j.1365-3083.1992.tb01645.x
4. Nakamura S, Yamakawa T, Sugita M, Kijima M, Ishioka M, Tanaka S, Ohno S (1994) The role of tumor necrosis factor-alpha in the induction of experimental autoimmune uveoretinitis in mice. Invest Ophthalmol Vis Sci 35:3884-3889
5. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G (1991) Transgenic mice expressing human tumor necrosis factor: a predictive genetic model of arthritis. EMBO J 10:4025-4031
6. Chilton F, Collet RA (2008) Treatment choices, preferences and decision-making by patients with rheumatoid arthritis. Musculoskeletal Care 6(1):1-14, doi: 10.1002/msc.110
7. Danese S, Panago N, Angelucci E et al (2007) Tumor necrosis factor-alpha monoclonal antibodies for Crohn's disease: Tipping the balance. Curr Med Chem 14(14):1489-1497, doi: 10.2174/092986707780831104
8. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN (2001) Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet 358:295-296, doi: 10.1016/ S0140-6736(01)05497-6
9. Reiff A, Takei S, Sadeghi S (2001) Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum 45:1411-1415 doi: 10.1002/ 1529-0131(200106)44:6<1411::AID-ART235>3.0.CO;2-O
10. Markomichelakis NN, Theodossiadis PG, Pantelia E, Papaefthimiou S, Theodossiadis GP, Sfikakis PP (2004) Infliximab for chronic cystoid macular edema associated with uveitis. Am J Ophthalmol 138:648-650, doi: 10.1016/j.ajo.2004.04.066
11. Nakazawa T, Nakazawa C, Matsubara A, Noda K, Hisatomi T, She H, Michaud N, Hafezi-Moghadam A, Miller JW, Benowitz LI (2006) Tumor necrosis factor-alpha mediates oligodendrocyte death and delayed retinal ganglion cell loss in a mouse model of glaucoma. J Neurosci 26(49):12633-12641, doi: 10.1523/JNEUROSCI.2801-06.2006
12. Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A (2006) A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and economic evaluation of their cost-effectiveness. Health Technol Assess. 10(42):iIi-iv, xi-xiii, 1-229
13. McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T (2007) Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: A systematic review and economic evaluation. Health Technol Assess 11(28):1-158
14. Ehlers S (2005) Why does tumor necrosis factor targeted therapy reactivate tuberculosis? J Rheumatol Suppl 74:35-39
15. Mukhopadhyay S, Hoidal JR, Mukherjee TK (2006) Role of TNF-alpha in pulmonary pathophysiology. Respir Res 7:125, doi: 10.1186/1465-9921-7-125
16. Lee JH, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel JN, Wise RP, Brown SL, Udall JN Jr, Braun MM (2002) Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 46(10):2565-2570, doi: 10.1002/art.10583
17. Sarzi-Puttini P, Atzeni F, Shoenfeld Y, Ferraccioli G (2005) TNF-alha, rheumatoid arthritis, and heart failure: A rheumatological dilemma. Autoimmun Rev 4(3):153-161, doi: 10.1016/j.autrev.2004.09.004
18. Selmaj K, Raine CS, Cross AH (1991) Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann Neurol 30(5):694-700, doi: 10.1002/ana.410300510
19. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM (2002) Tumor necrosis factor antagonist therapy and lymphoma development: Twenty six cases reported to the Food and Drug Administration. Arthritis Rheum 46(12):3151-3158, doi: 10.1002/art.10679
20. Lee HH, Song IH, Friedrich M, Gauliard A, Detert J, Röwert J, Audring H, Kary S, Burmester GR, Sterry W, Worm M (2007) Cutaneous side effects in patients with rheumatic diseases during application of tumor necrosis factor alpha antagonists. Br J Dermatol 156(3):486-491, doi: 10.1111/j.1365-2133.2007.07682.x
21. Tsilimbaris MK, Panagiotoglou TD, Charisis SK, Anastasakis A, Krikonis TS, Christodoulakis E (2007) The use of intravitreal etanercept in diabetic macular edema. Semin Ophthalmol 22(2):75-79, doi: 10.1080/ 08820530701418243
22. Bach M, Meigen T (1999) Do's and don'ts in Fourier analysis of steady state potentials. Doc Ophthalmol 99(1):69-82, doi: 10.1023/ A:1002648202420
23. Peyman GA (1977) Antibiotic administration in the treatment of bacterial endophthalmitis. II. Intravitreal injections. Surv Ophthalmol 21(332):339-346
24. Flynn HW Jr, Pulido JS, Pflugfelder SC, Davis JL, Culbertson WW, Roussel TJ, Miller D (1991) Endophthalmitis therapy: Changing antibiotic sensitivity patterns and current therapeutic recommendations. Arch Ophthalmol 109:175-176
25. Aydin E, Kazi AA, Peyman GA, Esfahani MR (2006) Intravitreal toxicity of moxifloxacin. Retina 26:187-190, doi: 10.1097/00006982-200602000-00011
26. Jager RD, Aiello LP, Patel SC, Cunningham ET Jr (2004) Risks of intravitreous injections: A comprehensive review. Retina 26:676-698, doi: 10.1097/00006982-200410000-00002
27. Goldstein M, Zemel E, Loewenstein A, Perlman I (2006) Retinal toxicity of indocyanine green in albino rabbits. Invest Ophthalmol Vis Sci 46(5):2100-2107, doi: 10.1167/iovs.05-0206
28. Manzano RP, Peyman GA, Carvounis PE, Kivilcim M, Khan P, Chevez-Barrios P, Takahashi W (2008) Ocular toxicity of intravitreous adalimumab (Humira) in the rabbit. Graefes Arch Clin Exp Ophthalmol 246(6):907-911, doi: 10.1007/s00417-008-0765-z
29. Fauser S, Kalbacher H, Alteheld N et al (2004) Pharmacokinetics and safety of intravitreally delivered etanercept. Graefes Arch Clin Exp Ophthalmol 242:582-586, doi: 10.1007/s00417-004-0895-x
30. Kivilcim M, Peyman GA, Kazi AA, Dellacroce J, Ghobrial RN, Manzano R (2007) Intravitreal toxicity of high-dose etanercept. J Ocul Pharmacol Ther 23(1):57-62, doi: 10.1089/jop.2006.0083
31. Giansanti F, Ramazzotti M, Vannozzi L, Rapizzi E, Fiore T, Iaccheri B, Degl' Innocenti D, Moncini D, Menchini U Invest Ophthalmol Vis Sci 49(3):1151-1156, doi: 10.1167/iovs.07-0932
32. Wick MC, Ernestam S, Lindblad S, Bratt J, Klareskog L, van Vollenhoven RF (2005) Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): Results from the STURE registry at Karolinska University Hospital. Scand J Rheumatol 34(5):353-358, doi: 10.1080/03009740510026887
33. Bennett AN, Peterson P, Zain A et al (2005) Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure. Rheumatology 44(8):1026-1031, doi: 10.1093/rheumatology/keh673
34. Kazi AA, Jermak CM, Peyman GA et al (2006) Intravitreal toxicity of levofloxacin and gatifloxacin. Ophthalmic Surg Lasers Imaging 37(3):224-229
35. Manzano RP, Peyman GA, Khan P et al (2006) Testing intravitreal toxicity of bevacizumab (Avastin). Retina 26(3):257-261, doi: 10.1097/ 00006982-200603000-00001
36. Yu SY, Damico FM, Viola F et al (2006) Retinal toxicity of intravitreal triamcinolone acetonide: A morphological study. Retina 26(5):531-536, doi: 10.1097/00006982-200605000-00006
37. Kim SJ, Adams NA, Toma HS et al (2008) Safety of intravitreal ketorolac and diclofenac: An electroretinographic and histopathologic study. Retina 28(4):595-605, doi: 10.1097/IAE.0b013e31815e98a5
38. Giansanti F, Ramazzotti M, Vannozzi L et al (2008) A pilot study on ocular safety of intravitreal infliximab in a rabbit model. Invest Ophthalmol Vis Sci 49(3):1151-1156, doi: 10.1167/iovs.07-0932
39. Lang Y, Zemel E, Miller B et al (2007) Retinal toxicity of intravitreal kenalog in albino rabbits. Retina 27(6):778-788, doi: 10.1097/ IAE.0b013e318030c517